Stock Research Monitor: GALT, KPTI, and LCI

LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want a free Stock Review on MNK sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com scans Galectin Therapeutics Inc. (NASDAQ: GALT), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Lannett Co. Inc. (NYSE: LCI), and Mallinckrodt PLC (NYSE: MNK). Companies in the Generic Drugs Manufacturing industry are capable of selling generic drugs at the lower price, because they are not required to repeat costly clinical trials and pay for marketing and promotion strategies. Patent expiration of branded drugs is one of the key influencers for the growth and prime reason for generating more revenue for this market. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Galectin Therapeutics

Norcross, Georgia-based Galectin Therapeutics Inc.'s stock finished Thursday's session 7.63% higher at $5.08. A total volume of 1.23 million shares was traded, which was above their three months average volume of 489,470 shares. Over the last month and the previous three months, the Company's shares have advanced 45.98% and 27.32%, respectively. Additionally, the stock has surged 123.79% over the past year. Shares of the Company are trading above their 50-day and 200-day moving averages by 27.25% and 51.79%, respectively. Moreover, shares of Galectin Therapeutics, which engages in the research and development of therapies for fibrotic disease and cancer, have a Relative Strength Index (RSI) of 69.39.

On May 14th, 2018, Galectin Therapeutics announced that the Company is proceeding with plans for a Phase-3 clinical trial program with its galectin-3 inhibitor GR-MD-02 in NASH cirrhosis, incorporating advice and guidance obtained in a meeting with the US Food and Drug Administration (FDA). Details of the Phase-3 clinical trial design, including projected timings and costs, will be announced once the planning phase has been completed and the Company has a final clinical trial protocol that is acceptable to the FDA. Get the full research report on GALT for free by clicking below at:

www.wallstequities.com/registration/?symbol=GALT

Karyopharm Therapeutics

Shares in Newton, Massachusetts headquartered Karyopharm Therapeutics Inc. rose slightly by 0.16%, ending yesterday's session at $18.58 with a total trading volume of 459,258 shares. The stock has gained 28.05% in the past month, 20.26% in the previous three months, and 128.82% over the past year. The Company's shares are trading 20.01% above their 50-day moving average and 49.53% above their 200-day moving average. Moreover, shares of Karyopharm Therapeutics, which focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases, have an RSI of 59.86.

On May 24th, 2018, research firm Wedbush downgraded the Company's stock rating from 'Outperform' to 'Neutral' while revising its previous target price from $20 a share to $19 a share.

On May 31st, 2018, Karyopharm Therapeutics announced that Michael Kauffman, MD, PhD, CEO, will participate in the following upcoming investor conferences: (i) Jefferies 2018 Global Healthcare Conference on June 07th, 2018, at 8:30 a.m. ET; and (ii) JMP Securities 2018 Life Sciences Conference on June 20th, 2018, at 8:00 a.m. ET. Find your free research report on KPTI at:

www.wallstequities.com/registration/?symbol=KPTI

Lannett

On Thursday, Philadelphia, Pennsylvania-based Lannett Co. Inc.'s stock dropped 1.78%, to close the day at $16.55. A total volume of 343,132 shares was traded. The Company's shares have advanced 4.09% in the last month and 3.12% in the previous three months. The stock is trading 4.03% above its 50-day moving average. Additionally, shares of Lannett, which develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the US, have an RSI of 55.60.

On May 21st, 2018, Lannett announced that the Company received approval from the US FDA of its Abbreviated New Drug Application for Dronabinol Capsules USP, 2.5 mg, 5 mg, and 10 mg, the therapeutic equivalent to the reference listed drug, Marinol® Capsules 2.5 mg, 5 mg, and 10 mg of AbbVie Inc. Sign up today for the free research report on LCI at:

www.wallstequities.com/registration/?symbol=LCI

Mallinckrodt

Shares in Staines-Upon-Thames, the UK-based Mallinckrodt PLC ended the day 1.58% lower at $16.85. A total volume of 2.42 million shares was traded. The stock has gained 28.63% in the last month and 7.46% in the previous three months. The Company's shares are trading above their 50-day moving average by 17.04%. Furthermore, shares of Mallinckrodt, which develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, Middle-Eastern, African, and the Asia/Pacific regions, have an RSI of 68.73.

On May 08th, 2018, Mallinckrodt reported its results for the three months ended March 30th, 2018. Net sales were $572.6 million in Q1 2018, GAAP gross profit was $276.8 million, and income tax benefit was $43.4 million. GAAP selling, general and administrative expenses for the quarter were $192.4 million, and research and development expenses were $64.1 million.

On May 09th, 2018, research firm Barclays reiterated its 'Underweight' rating on the Company's stock with a decrease of the target price from $20 a share to $12 a share. Wall St. Equities' research coverage also includes the downloadable free report on MNK at:

www.wallstequities.com/registration/?symbol=MNK

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities